NCT02521051View on ClinicalTrials.gov

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

September 28, 2015

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Alectinib

DRUG

Bevacizumab

Trial Locations (1)

02115

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER